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Key words: Biomarker, Osteoarthritis, Epidemiology.Dramatic advances in our understanding of the biochemis-
try of cartilage and of the ability to image biochemical and
structural changes within cartilage using magnetic reso-
nance imaging techniques have led to a cascade of studies
testing proteins and imaging ﬁndings as biomarkers of oste-
oarthritis (OA). Gene assay signatures and other signals of
molecular changes within the joint promise other exciting fu-
ture opportunities to characterize dynamic processes within
the joint.
In parallel with this progress has come an attempt by
a consortium of NIH investigators to deﬁne different cate-
gories of biomarkers in OA so that this growing ﬁeld can
use a common language and approach. The BIPED classi-
ﬁcation1 subclassiﬁes biomarkers according to whether
they are intended to provide information on burden of dis-
ease, be investigative, predict prognosis, reﬂect efﬁcacy
of treatment, or diagnose disease.
Despite these advances in cartilage biochemistry and
imaging, biomarkers have not emerged as accepted tools
for characterizing the status of the disease or its progno-
sis, nor as measures of treatment response, areas where
biomarker need is the greatest. It may be too early in the
evolution of this ﬁeld to expect such a change, and
numerous obstacles have been discussed: the inherently
slow rate of disease development, the lack of a gold stan-
dard for presence or absence of disease, the lack of stan-
dardized disease models and the absence of ways to
predictably modify disease in these models2,3. We
suggest that additional limitations in reporting results of
biomarker studies and in conceptualizing the role of bio-
markers in OA may be inhibiting advances. In the context
of these scientiﬁc and conceptual challenges, we propose
in this editorial to ﬁrstly reexamine the approach to report-
ing biomarker results and to secondly reconsider what in-
sights our current OA biomarker experience might provide
to the scientiﬁc community investigating OA. While most
directly relevant to biochemical markers of disease, this
editorial treats the topic of biomarkers broadly encom-
passing a range of approaches to measuring disease
processes.*Address correspondence and reprint requests to: Dr David T.
Felson, Suite 200, 650 Albany Street, Boston University School
of Medicine, Boston, MA 02118, United States. Tel: 1-617-638-
5180; Fax: 1-617-638-5239; E-mail: ncarras@bu.edu
419Is it a biomarker or a risk factor?
The NIH Biomarker’s Deﬁnitions Working Group in 2001
deﬁned a biomarker as a ‘‘characteristic that is objectively
measured and evaluated as an indicator of normal biologi-
cal processes or pharmacological responses to a therapeu-
tic intervention’’4. Interestingly, there is nothing in this
deﬁnition that requires a biomarker to measure disease or
a disease process. Since a biomarker by deﬁnition must re-
ﬂect normal biological processes or a response to a thera-
peutic intervention, validation of a marker thus deﬁned
requires some independent measure of that biological
process or of treatment response.
If the biological process being measured by the bio-
marker is a disease process, then the biomarker should
reﬂect disease occurrence. If, on the other hand, it is a bio-
logical process that may increase risk of disease ( for exam-
ple, the accumulation of advanced glycation end products in
osteoarthritic cartilage) and not necessarily a measure of
the disease or its change, then the parameter being mea-
sured should be tested as a risk factor and not as reﬂecting
a disease process. A risk factor is something that predis-
poses to the occurrence of disease or protects against it.
Well known risk factors include obesity for knee OA and
hypercholesterolemia for cardiovascular disease. The dis-
tinction between a risk factor and a disease biomarker is
sometimes not clear cut. For example, for advanced glyca-
tion end products, their presence as a constituent of mole-
cules within cartilage may change the stiffness of cartilage,
predisposing to disease (a risk factor) but, to the extent that
their presence in assays represents the release of long
standing molecules within cartilage and serves as a mea-
sure of cartilage turnover, they could also represent a dis-
ease process biomarker. Another example could be
matrix molecule fragments, which by their presence in car-
tilage matrix could elicit adverse cellular responses and be
regarded as a risk factor, while on the other hand they on
their release may represent a process marker.
The relationship of a risk factor to disease is usually
measured with relative risk or odds ratio measures, which
test whether those with a high level of a biomarker risk fac-
tor have a higher risk of disease or its progression than
those with a lower level. Identifying a risk factor for pro-
gression (e.g., obesity) creates the opportunity to develop
a treatment that eliminates this risk factor (e.g., weight
loss) to see if disease progression becomes less frequent.
While risk factors inﬂuence whether disease occurs,
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the disease process.Assessing diagnostic biomarkers
On the other hand, if a putative biomarker is being tested
as an indicator of disease or a disease process then it
needs to be compared to an independent ‘gold standard’
measure of disease. This assessment should include either
an evaluation of diagnostic test performance (e.g., sensitiv-
ity, speciﬁcity, positive and negative predictive value) or an
agreement statistic such as a kappa statistic or intraclass
correlation coefﬁcient.
COMP levels may reﬂect cartilage degradation. If COMP
represented a ‘risk factor’ for OA (e.g., if COMP caused car-
tilage loss), then one might envision developing interven-
tions that lowered the level of COMP so as to prevent
cartilage loss. One example might be to develop a drug
which metabolized COMP in the blood to lower its levels.
Obviously, this is not an appropriate intervention to reduce
OA progression, suggesting COMP should not be concep-
tualized or tested as a risk factor. COMP is instead a mea-
sure of cartilage matrix turnover and should be evaluated by
determining its accuracy in assessing that turnover. Using
a gold standard measure (e.g., cartilage loss over time),
a study might test whether high COMP levels predict those
likely to experience cartilage loss ( positive predictive value
for high COMP level) and whether low COMP levels identify
persons who experience little if any cartilage loss (a high
negative predictive value for a low COMP level).Biomarkers as measures of treatment response
Biomarkers could be valuable as measures of response
in OA, especially since traditional or morphological mea-
sures of response have been challenging to measure
and may not change rapidly over time. Successful bio-
markers have been developed as response measures in
other diseases including blood pressure and viral load in
HIV/AIDS. Yet others such as bone mineral density in os-
teoporosis have been advocated as good biomarkers but
may not necessarily reﬂect the efﬁcacy of treatment on
the major clinical outcome, fracture. This was the case,
for example, in ﬂuoride trials in which bone density mea-
surements suggested improvements on ﬂuoride treatment,
yet the trial outcome of fracture showed worsening in some
cases.
Ultimately, to be a valid measure of treatment response,
effects of the intervention on the biomarker ‘must reliably
predict the overall effect on the clinical outcome’5. As noted
by Fleming and DeMets, this requirement that the bio-
marker predict the overall effect of the clinical outcome fre-
quently underlies its failure. Reasons include the possibility
that the disease process can have several different ways of
affecting clinical outcome, only one of which is captured by
biomarker measurement. The most common misconception
is that a biomarker just needs to correlate with the outcome
( for example in the case of OA, this could translate into
a stabilization of COMP levels correlating with an absence
of cartilage loss over time). The biomarker must not only
correlate with the clinical outcome but also must capture
the net effect of treatment on the clinical outcome. This lat-
ter criterion is often very difﬁcult for a biomarker to satisfy.
Testing this latter requirement involves carrying out a clinical
trial or multiple trials that include measurements of the clin-
ical outcome and of the biomarker and testing whether thetreatment effect on the clinical outcome can be explained
either fully or in part by the biomarker.
Many studies of OA biomarkers have focused on mea-
sures of association such as relative risks or odds ratios
and few have adopted the more appropriate standard of di-
agnostic test evaluation to evaluate an indicator of disease
process. Recent studies6,7 have reported impressive odds
ratios associating a particular biochemical biomarker with
disease status but unimpressive diagnostic test perfor-
mance. Such biomarkers would not serve as valuable
diagnostic tests for OA.Validity and reliability of OA biomarkers
Concerns about OA biomarkers can be divided into con-
cerns about validity and reliability. In clinical epidemiology,
reliability means repeatabilitydwhether a given measure-
ment yields the same result when repeated at different
times of the day and in different circumstances and even
using the same assay in different laboratories. Kraus2 ex-
tensively reviewed sources of variability in the measure-
ment of biomarkers including whether food intake affects
their measurement, whether they ﬂuctuate diurnally,
whether they are affected by different activity states and
whether they vary based on drugs ingested. As Kraus
noted, we need better characterization of each biomarker
with respect to sources of variability so that these variations
can be minimized. Only when a biomarker is reliably
assessed can its true relation to the underlying disease
parameter of interest be gauged.
Although focused only on diagnostic markers, the
STARD initiative8 has provided a checklist of speciﬁc infor-
mation about biomarker measurement and the subjects
tested that should be provided in any study validating a bio-
marker regardless of its intended use. These include the fol-
lowing speciﬁc requirements: to blind those measuring the
marker as to disease status (in a study of prognosis, this
would mean blinding to prognosis status); to deﬁne the ra-
tionale for and selection of cutoffs differentiating ‘normal’
from ‘abnormal’ marker levels and importantly, to note the
source of subjects in a study, reporting whether they were
selected because of their biomarker status or unique clinical
ﬁndings (results in such preselected subjects would not
generalize to other persons).
Perhaps an even more serious concern in OA is the issue
of validity which is deﬁned as whether a biomarker mea-
sures what it is purported to measure. In the case of OA,
a diagnostic biomarker should measure whether disease
exists or not and a prognostic biomarker should predict
the trajectory of disease in individuals. The validity of bio-
markers depend on, among other things, whether a bio-
marker is close enough to the biological process so that
its level reﬂects that process. This is a special concern for
OA biomarkers derived from urine or blood and may be
less of a concern for an imaging biomarker from an affected
joint. For serum or urine, a cartilage degradation marker
originating in a single joint must be released from cartilage
into the synovial ﬂuid where it may be diluted by a large vol-
ume of ﬂuid. It must then be cleared through the synovial
membrane, and the rapidity of clearance is dependent prob-
ably on perfusion of the synovium and perhaps by the gra-
dients of levels of the biomarker in synovial ﬂuid vs blood9.
And then, in leaving the joint cavity, the circulating bio-
marker may be metabolized in synovial cells, lymph nodes
or liver to the point where assays of it no longer detect the
epitopes that originally identiﬁed it. It may then be further
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excretion. Its handling by the kidney will affect its levels in
urine. The farther away the specimen is from its origin in
the joint, the more challenging it is to tie a biomarker level
to ongoing processes in the individual joint.
The validity issue also relates to whether the process in
one joint is not so diluted by similar processes in other joints
as to be drowned out by the noise of biomarker release from
multiple joints or other cartilages in the body. It is no wonder
that COMP levels which may be diagnostic for OA are much
more strongly correlated with the occurrence of disease in
multiple joints than with the occurrence of disease in one10.
There are many formidable challenges to identifying
a joint speciﬁc biomarker, a molecule whose ﬂuctuation
within one or more joints is reﬂected by levels in the serum,
plasma or urine.
In addition, there is the conceptual issue of deﬁning the
location of the biological process that the biomarker is ex-
pected to assess. Since OA often occurs in joints that are
asymptomatic and may not have been imaged, the disease
process may be far more widespread than indicated by
clinical evaluation. This may compromise an investigator’s
ability to detect a relation of the putative biomarker with dis-
ease in a single target joint since the involvement of other
joints through the body is unknown and may vary from
person to person. Also, OA is not a disease relegated to
cartilage alone, so that a marker may need to be speciﬁed
as reﬂecting cartilage turnover and not necessarily disease
per se. To the extent that some markers measured or pro-
posed originate not just in hyaline cartilage but also in ﬁbro-
cartilage (meniscus) and even synovium, the biological
process being assessed needs to be characterized accu-
rately. The recognition that bone turnover is involved in
OA has created an opportunity for the development of bio-
markers of bone as reﬂectors of the dynamic process of
OA but, just as levels of cartilage biomarkers are affected
by the biological dynamism of multiple joints, systemic bio-
markers of bone will reﬂect systemic processes within bone
in general and not just turnover within a small area of one
joint.
Biomarkers that reﬂect cartilage turnover may fail to
show strong correlations with the underlying biological pa-
rameter, cartilage turnover, not because the biomarkers do
not reﬂect their intended target well but because we have
been unable to measure cartilage turnover successfully.
First, cartilage turnover or enhanced synthesis and degra-
dation of matrix is not the same as the cartilage loss which
is the focus of clinical studies. Second, cartilage loss is
challenging to assess. Progressive joint space narrowing
on X-ray over time is probably an inadequate measure of
such loss because, at least in the knee, it can reﬂect
change in meniscal position and is insensitive to cartilage
loss11. For knee MRI, cartilage loss may be painfully
slow. Morphological tissue loss may actually not be the
biological parameter of interest but rather change in the
composition of cartilage.
Interesting lessons were recently provided by what was
felt to be a well characterized biomarker of hyaline cartilage
degradation, CTX2, representing cross-linked fragments of
the C-telopeptide of type II collagen12. This biomarker, as-
sumed to result only from the proteolytic degradation of
type II collagen in hyaline cartilage matrix was shown to re-
ﬂect both the presence of OA, and to predict its develop-
ment13. Animal model data and results from a pilot human
study using risedronate, a bisphosphonate, showed that
urine levels of CTX2 were dramatically decreased by risedr-
onate treatment, together with expected decreases on boneturnover marker levels. These results were conﬁrmed in
a large randomized clinical trial of knee OA. However,
neither knee joint structure as monitored by standardized
radiographs nor symptoms were affected by risedronate
treatment over 2 years7. We may conclude based on other
studies, that CTX2 might be a diagnostic or even a predic-
tive biomarker: however, it failed as a biomarker to reﬂect
efﬁcacy of response in this trial. As noted earlier in this re-
view, one reason for this paradoxical result could be that the
standard radiographic assessment used in this trial was not
sensitive enough to detect the effects of risedronate on os-
teoarthritic cartilage. Were this true, it would still leave us
concerned as to why the putative beneﬁcial effects of risedr-
onate on cartilage did not translate into a patient-reported
beneﬁt over 2 years. Beyond the challenges in proving
structural change or its absence by imaging, we may con-
sider other reasons why the earlier CTX2 data might have
been misleading in this instance. While hyaline cartilage is
the dominant source of type II collagen, contributions to cir-
culating levels of CTX2 coming from calciﬁed cartilage in
the tidemark, or even from bone, cannot be excluded. Since
the calciﬁed cartilage in the tidemark is affected in OA, and
both bone and calciﬁed cartilage turnover are powerfully af-
fected by risedronate14,the systemic CTX2 signal resulting
from risedronate treatment may originate, in part, from cal-
ciﬁed cartilage or even bone3,15. Unless we understand
the details of how the biomarker is generated, and where,
we risk being misled.
To advance the science of OA biomarkers, we may need
to skip much of what would be the usual validation work be-
cause our biological parameter of interest, change in OA, is
not readily measured. The lack of treatments which prevent
morphological deterioration in the joint, presents great difﬁ-
culties for biomarker development. Without such treatments
and without measures of morphological change in OA, the
development and validation of biomarkers in OA will
continue to be a huge challenge.
It is our view that biomarkers will likely not be successful
as diagnostic tests for OA. For success to be achieved in
this area, we must be able to identify persons without OA
of a similar age to those with disease. Without a compre-
hensive imaging survey of both cases and controls, it will
be impossible to determine whether older controls actually
have the disease. Further, the difﬁculty in comprehensively
imaging joints of supposed cases with OA will make as-
sessing the burden of OA in ‘cases’ similarly difﬁcult.
Most of the markers being tested are not markers of
disease status but rather markers which reﬂect cartilage
turnover and turnover in other joint structures. Just as in
osteoporosis where markers reﬂect synthesis and degrada-
tion of bone and not bone density, an assessment of the
anabolic and catabolic activities of joint structures will not
be reﬂected in static imaging measures such as conven-
tional Magnetic Resonance Imaging (MRI) or X-ray. It is
possible that imaging techniques focusing on biochemical
composition of cartilage such as delayed Gadolinium En-
hanced MRI of Cartilage (dGEMRIC) and T1RHO will be
more helpful than images of joint anatomy.
In conclusion, the barriers for validating and using OA
biomarkers are formidable. One barrier relates to failures
in imaging osteoarthritic changes so as to facilitate valida-
tion of biomarkers. Another relates to the complexity of
OA, which is not a homogeneous disease. Not only does
it affect more than just one joint, but different persons with
OA have different regions and structures within the joint af-
fected, each of which may produce its own characteristic
biomarker proﬁle. Yet other barriers to discovery are posed
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may be affected by disease and thus contribute to the bio-
marker signal detected. This barrier is further heightened by
selecting serum or urine markers which are distant from the
pathologic process within a single joint. Since biomarkers
may ideally measure the dynamic processes within affected
joints, validating them against the disease state of the joint
and not its change may be inappropriate.
Given these challenges, what questions can biomarkers
successfully address? We suggest that there are opportuni-
ties in the development of biomarkers which relate ﬁrst to the
use of biomarkers as a tool to understand the pathophysio-
logic process of cartilage loss and change in other joint struc-
tures.We suggest further that, unlike in someother diseases,
the development of biomarker science in OA may have to
jump over and even ignore limitations in morphological as-
sessment of the joint. Conventional approaches using risk
factor analyses andX-rays to evaluate the relation of putative
markers with these disease parameters are not likely to be as
revealing as studies of new imaging biomarkers, in part be-
cause such imaging may produce insights into pathophysiol-
ogy and is proximate to the site of pathology. Changes in
biomarkers with treatment may reﬂect real effects of treat-
ment and may signal that biomarkers can detect these
changes even though wemay not yet have sensitive enough
measures of morphologic change to assess them or under-
stand their signiﬁcance. Any proposed diagnostic biomarker
needs to be tested not as a risk factor but as a diagnostic test.
Validation of other biomarkers (e.g., treatment response)
needs to be purpose speciﬁc. The ﬁnal proof of utility will
probably require a large and long-term prospective study
with clear a priori hypotheses.Conﬂict of interest
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